Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection

Ciro Costagliola, Aurora Daniele, Roberto dell'Omo, Mario R. Romano, Fabiana Aceto, Luca Agnifili, Francesco Semeraro, Antonio Porcellini

Research output: Contribution to journalArticle

Abstract

To determine the levels of vascular endothelial growth factor (VEGF) and adiponectin (APN) in the aqueous humor of patients with type 2 diabetes before and after injection of bevacizumab (IVB). Twenty eyes of twenty consecutive patients with type 2 diabetes with PDR and clinically significant macular edema were enrolled in this study. Aqueous samples were collected at baseline and one month after IVB to evaluate VEGF and APN levels. Twenty age-matched patients undergoing cataract surgery were used as control. Best-corrected visual acuity (BCVA) and foveal thickness (FT) changes after IVB were also measured. Safety was assessed by recording the incidence of ocular and non-ocular adverse events. At baseline APN and VEGF levels were significantly lower in controls than in PDR patients (APN: 3.6 ± 1.1 vs 18.7 ± 4.5 ng/ml; VEGF: 22.6 ± 16.1 vs 146.2 ± 38.71 pg/ml). After IVB, both compounds significantly decreased. FT and BCVA at baseline were significantly different between controls and patients (FT: 215.6 ± 34.8 vs 532.7 ± 112.4 μm; BCVA: 23.6 ± 4.2 vs 18.4 ± 7.3 letters). After IVB a significant decrease of FT with a concomitant improvement of BCVA occurred. Neither ocular nor systemic adverse events were reported. Our findings demonstrate that patients with type 2 diabetes, PDR and macular edema show VEGF and APN levels in aqueous humor higher than those found in control subjects. IVB significantly reduced the levels of both compounds, which remained anyway at concentrations higher than those recorded in control subjects.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalExperimental Eye Research
Volume110
DOIs
Publication statusPublished - May 2013

Fingerprint

Intravitreal Injections
Aqueous Humor
Adiponectin
Type 2 Diabetes Mellitus
Vascular Endothelial Growth Factor A
Visual Acuity
Macular Edema
Cataract
Bevacizumab
Safety
Injections
Incidence

Keywords

  • Adiponectin
  • Aqueous humor
  • Diabetic macular edema
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. / Costagliola, Ciro; Daniele, Aurora; dell'Omo, Roberto; Romano, Mario R.; Aceto, Fabiana; Agnifili, Luca; Semeraro, Francesco; Porcellini, Antonio.

In: Experimental Eye Research, Vol. 110, 05.2013, p. 50-54.

Research output: Contribution to journalArticle

Costagliola, Ciro ; Daniele, Aurora ; dell'Omo, Roberto ; Romano, Mario R. ; Aceto, Fabiana ; Agnifili, Luca ; Semeraro, Francesco ; Porcellini, Antonio. / Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. In: Experimental Eye Research. 2013 ; Vol. 110. pp. 50-54.
@article{116e5d09bb71495aa5381db5692752e7,
title = "Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection",
abstract = "To determine the levels of vascular endothelial growth factor (VEGF) and adiponectin (APN) in the aqueous humor of patients with type 2 diabetes before and after injection of bevacizumab (IVB). Twenty eyes of twenty consecutive patients with type 2 diabetes with PDR and clinically significant macular edema were enrolled in this study. Aqueous samples were collected at baseline and one month after IVB to evaluate VEGF and APN levels. Twenty age-matched patients undergoing cataract surgery were used as control. Best-corrected visual acuity (BCVA) and foveal thickness (FT) changes after IVB were also measured. Safety was assessed by recording the incidence of ocular and non-ocular adverse events. At baseline APN and VEGF levels were significantly lower in controls than in PDR patients (APN: 3.6 ± 1.1 vs 18.7 ± 4.5 ng/ml; VEGF: 22.6 ± 16.1 vs 146.2 ± 38.71 pg/ml). After IVB, both compounds significantly decreased. FT and BCVA at baseline were significantly different between controls and patients (FT: 215.6 ± 34.8 vs 532.7 ± 112.4 μm; BCVA: 23.6 ± 4.2 vs 18.4 ± 7.3 letters). After IVB a significant decrease of FT with a concomitant improvement of BCVA occurred. Neither ocular nor systemic adverse events were reported. Our findings demonstrate that patients with type 2 diabetes, PDR and macular edema show VEGF and APN levels in aqueous humor higher than those found in control subjects. IVB significantly reduced the levels of both compounds, which remained anyway at concentrations higher than those recorded in control subjects.",
keywords = "Adiponectin, Aqueous humor, Diabetic macular edema, Proliferative diabetic retinopathy, Vascular endothelial growth factor",
author = "Ciro Costagliola and Aurora Daniele and Roberto dell'Omo and Romano, {Mario R.} and Fabiana Aceto and Luca Agnifili and Francesco Semeraro and Antonio Porcellini",
year = "2013",
month = "5",
doi = "10.1016/j.exer.2013.02.004",
language = "English",
volume = "110",
pages = "50--54",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection

AU - Costagliola, Ciro

AU - Daniele, Aurora

AU - dell'Omo, Roberto

AU - Romano, Mario R.

AU - Aceto, Fabiana

AU - Agnifili, Luca

AU - Semeraro, Francesco

AU - Porcellini, Antonio

PY - 2013/5

Y1 - 2013/5

N2 - To determine the levels of vascular endothelial growth factor (VEGF) and adiponectin (APN) in the aqueous humor of patients with type 2 diabetes before and after injection of bevacizumab (IVB). Twenty eyes of twenty consecutive patients with type 2 diabetes with PDR and clinically significant macular edema were enrolled in this study. Aqueous samples were collected at baseline and one month after IVB to evaluate VEGF and APN levels. Twenty age-matched patients undergoing cataract surgery were used as control. Best-corrected visual acuity (BCVA) and foveal thickness (FT) changes after IVB were also measured. Safety was assessed by recording the incidence of ocular and non-ocular adverse events. At baseline APN and VEGF levels were significantly lower in controls than in PDR patients (APN: 3.6 ± 1.1 vs 18.7 ± 4.5 ng/ml; VEGF: 22.6 ± 16.1 vs 146.2 ± 38.71 pg/ml). After IVB, both compounds significantly decreased. FT and BCVA at baseline were significantly different between controls and patients (FT: 215.6 ± 34.8 vs 532.7 ± 112.4 μm; BCVA: 23.6 ± 4.2 vs 18.4 ± 7.3 letters). After IVB a significant decrease of FT with a concomitant improvement of BCVA occurred. Neither ocular nor systemic adverse events were reported. Our findings demonstrate that patients with type 2 diabetes, PDR and macular edema show VEGF and APN levels in aqueous humor higher than those found in control subjects. IVB significantly reduced the levels of both compounds, which remained anyway at concentrations higher than those recorded in control subjects.

AB - To determine the levels of vascular endothelial growth factor (VEGF) and adiponectin (APN) in the aqueous humor of patients with type 2 diabetes before and after injection of bevacizumab (IVB). Twenty eyes of twenty consecutive patients with type 2 diabetes with PDR and clinically significant macular edema were enrolled in this study. Aqueous samples were collected at baseline and one month after IVB to evaluate VEGF and APN levels. Twenty age-matched patients undergoing cataract surgery were used as control. Best-corrected visual acuity (BCVA) and foveal thickness (FT) changes after IVB were also measured. Safety was assessed by recording the incidence of ocular and non-ocular adverse events. At baseline APN and VEGF levels were significantly lower in controls than in PDR patients (APN: 3.6 ± 1.1 vs 18.7 ± 4.5 ng/ml; VEGF: 22.6 ± 16.1 vs 146.2 ± 38.71 pg/ml). After IVB, both compounds significantly decreased. FT and BCVA at baseline were significantly different between controls and patients (FT: 215.6 ± 34.8 vs 532.7 ± 112.4 μm; BCVA: 23.6 ± 4.2 vs 18.4 ± 7.3 letters). After IVB a significant decrease of FT with a concomitant improvement of BCVA occurred. Neither ocular nor systemic adverse events were reported. Our findings demonstrate that patients with type 2 diabetes, PDR and macular edema show VEGF and APN levels in aqueous humor higher than those found in control subjects. IVB significantly reduced the levels of both compounds, which remained anyway at concentrations higher than those recorded in control subjects.

KW - Adiponectin

KW - Aqueous humor

KW - Diabetic macular edema

KW - Proliferative diabetic retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84875660152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875660152&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2013.02.004

DO - 10.1016/j.exer.2013.02.004

M3 - Article

C2 - 23454098

AN - SCOPUS:84875660152

VL - 110

SP - 50

EP - 54

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

ER -